Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720
26 févr. 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
04 févr. 2019 07h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial
29 janv. 2019 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
07 janv. 2019 16h01 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
07 janv. 2019 07h30 HE
|
Spero Therapeutics, Inc.
FDA meeting supports single pivotal Phase 3 clinical trial of SPR994 in cUTISPR994 IND submitted and ADAPT-PO Phase 3 startup activities underway CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) --...
Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview
08 nov. 2018 16h10 HE
|
Spero Therapeutics, Inc.
Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE)...
Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
05 nov. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
11 oct. 2018 08h00 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
27 sept. 2018 16h01 HE
|
Spero Therapeutics, Inc.
Multiple ascending dose clinical data supports advancement of 600 mg TID dose for pivotal Phase 3 clinical trial, planned for initiation around year-end 2018600 mg dose provides greater drug exposure...
Spero Therapeutics Announces Presentations at IDWeek 2018
25 sept. 2018 16h01 HE
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...